References:
1. Huang C, Wang Y, Li X et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet2020; 395 (10223): 497-506.
2. Richardson S, Hirsch JS, Narasimhan M et al. . Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA 2020.
3. Grasselli G, Zangrillo A, Zanella A et al. . Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020;323 (16): 1574.
4. Joseph AO, Joseph JP, Pereira B, Gahir J. Coronavirus outbreak: Reorganising the breast unit during a pandemic. Eur J Surg Oncol2020.
5. Golonka RM, Saha P, Yeoh BS et al. . Harnessing innate immunity to eliminate SARS-CoV-2 and ameliorate COVID-19 disease. PHYSIOL GENOMICS 2020; 52 (5): 217-221.
6. Lian J, Jin X, Hao S et al. . Epidemiological, clinical, and virological characteristics of 465 hospitalized cases of coronavirus disease 2019 (COVID-19) from Zhejiang province in China. Influenza Other Respir Viruses 2020.
7. Arachchillage D, Laffan M. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J THROMB HAEMOST 2020; 18 (5):1233-1234.
8. Cardoso FS, Pereira R, Germano N. Liver injury in critically ill patients with COVID-19: a case series. CRIT CARE 2020;24 (1).
9. Johnson KM, Belfer JJ, Peterson GR, Boelkins MR, Dumkow LE. Managing COVID-19 in Renal Transplant Recipients: A Review of Recent Literature and Case Supporting Corticosteroid-sparing Immunosuppression.PHARMACOTHERAPY 2020.
10. Chen F, Chan KH, Jiang Y et al. . In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds. J CLIN VIROL 2004; 31 (1): 69-75.
11. Chan JF, Chan KH, Kao RY et al. . Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Infect 2013; 67 (6): 606-616.
12. Shalhoub S, Farahat F, Al-Jiffri A et al. . IFN-alpha2a or IFN-beta1a in combination with ribavirin to treat Middle East respiratory syndrome coronavirus pneumonia: a retrospective study.J Antimicrob Chemother 2015; 70 (7): 2129-2132.
13. Cao B, Wang Y, Wen D et al. . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med 2020;382 (19): 1787-1799.
14. Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. SEMIN IMMUNOPATHOL 2017;39 (5): 529-539.
15. Andreakos E, Tsiodras S. COVID‐19: lambda interferon against viral load and hyperinflammation. EMBO MOL MED 2020.
16. Channappanavar R, Fehr AR, Vijay R et al. . Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice. CELL HOST MICROBE 2016;19 (2): 181-193.
17. Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle East respiratory syndrome coronavirus: an observational study. INT J INFECT DIS 2014;20: 42-46.
18. Lu H. Drug treatment options for the 2019-new coronavirus (2019-nCoV). BIOSCI TRENDS 2020; 14 (1): 69-71.
19. Alhazzani W, Moller MH, Arabi YM et al. . Surviving Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus Disease 2019 (COVID-19). Intensive Care Med 2020;46 (5): 854-887.
20. Omrani AS, Saad MM, Baig K et al. . Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. The Lancet Infectious Diseases 2014; 14 (11): 1090-1095.
21. Dalbjerg SM, Tsakiri A, Frederiksen JL. Rhabdomyolysis following interferon-beta treatment in a patient with multiple sclerosis - A case report. Mult Scler Relat Disord 2016; 8: 93-95.
22. Dos SA, Guardia AC, Pereira TS et al. . Rhabdomyolysis as a clinical manifestation of association with ciprofibrate, sirolimus, cyclosporine, and pegylated interferon-alpha in liver-transplanted patients: a case report and literature review. Transplant Proc2014; 46 (6): 1887-1888.
23. Yuan J, Zou R, Zeng L et al. . The correlation between viral clearance and biochemical outcomes of 94 COVID-19 infected discharged patients. INFLAMM RES 2020; 69 (6): 599-606.